Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2Breast Neoplasms 2Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blood Protein Disorders 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Tamoxifen 12Early Intervention, Educational 7Methods 6Practice Guidelines as Topic 5Neoadjuvant Therapy 5Immunohistochemistry 5Counseling 5Chemotherapy, Adjuvant 5Anastrozole 5Standard of Care 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Mastectomy, Segmental 4Mass Spectrometry 4Letrozole 4Educational Status 4Behavior Therapy 4Gene Expression Profiling 3Biopsy 3exemestane 2Telemedicine 2Taxes 2Surveys and Questionnaires 2Soybean Proteins 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiosurgery 2Radiation Dose Hypofractionation 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Carcinoma In Situ × Ranitidine × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡